Seeking Alpha
 

Aethlon Medical, Inc. (AEMD)

- OTCQB
  • Fri, Feb. 20, 7:15 AM
    • The World Health Organization (WHO) approves the use of a 15-minute point-of-care test developed by Corgenix Medical (OTCQB:CONX) to detect the presence of the Ebola virus. The company developed the assay with funding assistance of the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation.
    • Procurement and roll-out in Africa will begin in a few weeks pending the completion of administrative procedures with the U.S. FDA.
    • Ebola-related tickers: (NYSE:MRK) (NASDAQ:NLNK) (NYSEMKT:IBIO) (NASDAQ:NVAX) (NYSE:GSK) (NYSE:JNJ) (NASDAQ:TKMR) (NYSEMKT:HEB) (NASDAQ:BCRX) (NASDAQ:SRPT) (NASDAQ:CMRX) (NASDAQ:ABIO) (OTCQB:AEMD) (OTCPK:BVNRY) (NASDAQ:INO) (OTCQX:RHHBY)
    | 10 Comments
  • Dec. 31, 2014, 7:23 AM
    • The FDA approves Aethlon Medical's (OTCQB:AEMD) Investigational Device Exemption (IDE) supplement allowing the use of Hemopurifier to treat patients infected with the Ebola virus. Under the terms of the approval, the company may treat up to 20 U.S. patients at no more than 10 sites.
    • The original IDE covered the use of the device in patients infected with the hepatitis C virus.
    • Previously: Aethlon Medical up on successful Ebola treatment (Nov. 17)
    | 10 Comments
  • Dec. 5, 2014, 7:19 AM
    • Doctors say that simple intravenous fluid drips could save the lives of many Ebola patients, but they are not being deployed due to a perception that no treatment will work.  Many patients are succumbing to extreme dehydration and electrolyte depletion caused by vomiting and diarrhea, according to Ian Roberts of the London School of Hygiene and Tropical Medicine and Anders Perner of Copenhagen University. "Ebola treatment must be more that just a setting for quarantine. Patients will be reluctant to attend treatment centers unless the care they receive...is superior to the care provided by family members."
    • The epidemic in West Africa has claimed more than 6,000 lives out of ~17,000 that have been infected. All but 15 of the deaths have occurred in Sierra Leone, Guinea and Liberia.
    • ETFs: IRY, IXJ
    • Ebola-related tickers: (NYSE:GSK) (NYSE:JNJ) (NYSE:MRK) (NASDAQ:NLNK) (OTCQB:AEMD) (NASDAQ:TKMR) (NYSEMKT:HEB) (NASDAQ:SRPT) (NASDAQ:BCRX)
    | 8 Comments
  • Nov. 26, 2014, 10:14 AM
    • Nebraska Medical Center has received four Hemopurifiers from Aethlon Medical (OTCQB:AEMD +17.4%) to stockpile for future Ebola treatments. The company has also completed onsite training for clinical personnel related to the implementation of Hemopurifier therapy within the dialysis infrastructure currently located at the center.
    • Previously: Aethlon Medical up on successful Ebola treatment
    | Comment!
  • Nov. 24, 2014, 1:43 PM
    • Nano cap Aethlon Medical (OTCQB:AEMD +31.8%) jumps on turnover of 22M. Shares are up almost seven-fold from mid-September and still haven't breached $0.70.
    • The company recently reported successful results with its Hemopurifier bio-filtration device on an Ebola patient.
    • Previously: Aethlon Medical up on successful Ebola treatment
    | 12 Comments
  • Nov. 20, 2014, 11:03 AM
    • The Securities and Exchange Commission suspends trading in thinly-traded nano caps Bravo Enterprises (OTCQB:OGNG), Immunotech Labs (OTCPK:IMMB), Myriad Interactive Media (MYRY) and Wholehealth Products (OTCPK:GWPC) citing a lack of publicly available information about the firms' operations.
    • The SEC can suspend trading in a stock for 10 days and prohibit broker-dealers from soliciting buyers and sellers until certain reporting requirements are met.
    • Ebola Small Cap Index (based on trading behavior): (OTCQB:AEMD -7%)(HEB +1.4%)(TKMR +0.2%)(NLNK +5.4%)(NNVC +2.9%)(INO +5%)(OTCQB:GOVX -2.1%)(SRPT +3.5%)(CMRX -1.3%)(PLX -0.9%)(NSPH -1.4%)(BCRX +0.4%)(LAKE -1.9%)(APT -2.4%)(VSR)(SMED +0.7%)
    | 2 Comments
  • Nov. 17, 2014, 12:06 PM
    • Nano cap Aethlon Medical (OTCQB:AEMD +29.8%) jumps on massive turnover of 10M shares in response to its report of the successful treatment of a critically-ill Ebola patient in Germany with its Hemopurifier bio-filtration device. In a post-treatment analysis, the device captured 242M Ebola viruses. The patient is expected to make a full recovery.
    • The Hemopurifier targets the broad-spectrum elimination of viruses and immunosuppressive proteins from the blood.
    • The stock has more than tripled since mid-October when the first treatment with the Hemopurifier was reported.
    • Some of the members of the trading behavior-characterized Ebola Small Cap Index have completed their round trips. (HEB +1.2%)(TKMR +5.1%)(NLNK +2.5%)(NNVC -3.8%)(INO -8.5%)(OTCQB:GOVX)(SRPT -0.7%)(CMRX +4.4%)(PLX -1%)(NSPH -0.2%)(BCRX +0.7%)(LAKE +1.3%)(APT +0.2%)(VSR -0.7%)(SMED -2.7%)
    | 19 Comments
Visit Seeking Alpha's
AEMD vs. ETF Alternatives
Company Description
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to... More